NYSE · CIK 0001811063
NUVB Nuvation Bio Inc.
Insider trading from SEC Form 4. Last filing Mar 3, 2026. Close $5.00 on Oct 9, 2026, +47% from the 52-week low and -48% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
16
with a Form 4 at this company
Price and insider trades, last year
NUVBOct 9, 2026 · close 5.00
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Nuvation Bio Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 60Notable | Dongfang Liu CHIEF MEDICAL OFFICER sell | $1.2M 150,000 shares | -89% | +375% from low-2% from high | |
| 46Moderate | Dongfang Liu CHIEF MEDICAL OFFICER sell | $155k 20,000 shares | -71% | +375% from low0% from high | |
| 60Notable | Gary Hattersley CHIEF SCIENTIFIC OFFICER sell | $2.7M 369,051 shares | -534% | +322% from low-2% from high | |
| 46Moderate | Dongfang Liu CHIEF MEDICAL OFFICER sell | $140k 20,000 shares | -53% | +322% from low-2% from high | |
| 60Notable | David C. Hanley CHIEF TECHNICAL OPERATIONS sell | $1.4M 200,000 shares | -89% | +331% from low0% from high | |
| 46Moderate | Dongfang Liu CHIEF MEDICAL OFFICER sell | $148k 30,000 shares | -100% | +181% from low-13% from high | |
| 18Weak | Gary Hattersley CHIEF SCIENTIFIC OFFICER sell | $502k 100,000 shares | -100% | +204% from low0% from high | |
| 72Notable | David Hung PRESIDENT AND CEO buy | $894k 500,000 shares | +1% | +12% from low-43% from high | |
| 58Moderate | Stacy Markel CHIEF PEOPLE OFFICER buy | $17k 10,000 shares | +51% | +8% from low-45% from high | |
| 55Moderate | Kerry Wentworth CHIEF REGULATORY OFFICER buy | $90k 50,000 shares | - | +12% from low-43% from high | |
| 57Moderate | Colleen Sjogren Chief Commercial Officer buy | $90k 50,000 shares | +161% | +12% from low-43% from high | |
| 55Moderate | Philippe Sauvage Chief Financial Officer buy | $13k 7,300 shares | +281% | +12% from low-43% from high | |
| 7Weak | Dongfang Liu CHIEF MEDICAL OFFICER sell | $50k 20,000 shares | -63% | +48% from low-24% from high | |
| 68Notable | David Hung PRESIDENT AND CEO buy | $820k 500,000 shares | +1% | 0% from low-49% from high | |
| 62Notable | Robert Mashal director buy | $167k 100,000 shares | +100% | 0% from low-46% from high | |
| 36Weak | Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD. sell | $163k 56,361 shares | -1% | - |
Transactions
The last 66 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | David C. Hanley CHIEF TECHNICAL OPERATIONS | AGrant or award Stock Option (Right to Buy)derivative | +748,130 | $0.00 | $0 | 748,130 | Mar 3, 2026 |
| Feb 27, 2026 | Gary Hattersley CHIEF SCIENTIFIC OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +748,130 | $0.00 | $0 | 748,130 | Mar 3, 2026 |
| Feb 27, 2026 | David Hung PRESIDENT AND CEO | AGrant or award Stock Option (Right to Buy)derivative | +1,995,012 | $0.00 | $0 | 1,995,012 | Mar 3, 2026 |
| Feb 27, 2026 | Dongfang Liu CHIEF MEDICAL OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +748,130 | $0.00 | $0 | 748,130 | Mar 3, 2026 |
| Feb 27, 2026 | Moses Makunje SEE REMARKS | AGrant or award Class A Common Stock | +50,761 | $0.00 | $0 | 68,137 | Mar 3, 2026 |
| Feb 27, 2026 | Xiangmin Cui director | AGrant or award Stock Option (Right to Buy)derivative | +74,813 | $0.00 | $0 | 74,813 | Mar 3, 2026 |
| Feb 27, 2026 | Moses Makunje SEE REMARKS | AGrant or award Stock Option (Right to Buy)derivative | +224,439 | $0.00 | $0 | 224,439 | Mar 3, 2026 |
| Feb 27, 2026 | Stacy Markel CHIEF PEOPLE OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +748,130 | $0.00 | $0 | 748,130 | Mar 3, 2026 |
| Feb 27, 2026 | Kerry Wentworth CHIEF REGULATORY OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +748,130 | $0.00 | $0 | 748,130 | Mar 3, 2026 |
| Feb 27, 2026 | Colleen Sjogren Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +748,130 | $0.00 | $0 | 748,130 | Mar 3, 2026 |
| Feb 27, 2026 | Philippe Sauvage Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +748,130 | $0.00 | $0 | 748,130 | Mar 3, 2026 |
| Dec 1, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Class A Common Stock | +150,000 | $2.93 | $440k | 168,000 | Dec 3, 2025 |
| Dec 1, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | SOpen-market sale Class A Common Stock | -150,000 | $7.82 | $1.2M | 18,000 | Dec 3, 2025 |
| Dec 1, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Stock Option (Right to Buy)derivative | -150,000 | $0.00 | $0 | 165,000 | Dec 3, 2025 |
| Nov 25, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Class A Common Stock | +10,000 | $3.61 | $36k | 28,000 | Nov 26, 2025 |
| Nov 25, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | SOpen-market sale Class A Common Stock | -10,000 | $7.50 | $75k | 18,000 | Nov 26, 2025 |
| Nov 26, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Class A Common Stock | +10,000 | $3.61 | $36k | 28,000 | Nov 26, 2025 |
| Nov 26, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | SOpen-market sale Class A Common Stock | -10,000 | $8.00 | $80k | 18,000 | Nov 26, 2025 |
| Nov 25, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Stock Option (Right to Buy)derivative | -10,000 | $0.00 | $0 | 480,000 | Nov 26, 2025 |
| Nov 26, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Stock Option (Right to Buy)derivative | -10,000 | $0.00 | $0 | 470,000 | Nov 26, 2025 |
| Nov 20, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Class A Common Stock | +20,000 | $1.87 | $37k | 38,000 | Nov 24, 2025 |
| Nov 20, 2025 | Gary Hattersley CHIEF SCIENTIFIC OFFICER | MOption exercise Class A Common Stock | +69,051 | $1.74 | $120k | 69,051 | Nov 24, 2025 |
| Nov 20, 2025 | Gary Hattersley CHIEF SCIENTIFIC OFFICER | SOpen-market sale Class A Common Stock | -69,051 | $7.23 | $499k | 0 | Nov 24, 2025 |
| Nov 20, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | SOpen-market sale Class A Common Stock | -20,000 | $7.00 | $140k | 18,000 | Nov 24, 2025 |
| Nov 20, 2025 | Gary Hattersley CHIEF SCIENTIFIC OFFICER | MOption exercise Class A Common Stock | +300,000 | $1.94 | $582k | 300,000 | Nov 24, 2025 |
| Nov 20, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Stock Option (Right to Buy)derivative | -20,000 | $0.00 | $0 | 450,000 | Nov 24, 2025 |
| Nov 20, 2025 | Gary Hattersley CHIEF SCIENTIFIC OFFICER | SOpen-market sale Class A Common Stock | -300,000 | $7.23 | $2.2M | 0 | Nov 24, 2025 |
| Nov 20, 2025 | Gary Hattersley CHIEF SCIENTIFIC OFFICER | MOption exercise Stock Option (Right to Buy)derivative | -69,051 | $0.00 | $0 | 229,884 | Nov 24, 2025 |
| Nov 20, 2025 | Gary Hattersley CHIEF SCIENTIFIC OFFICER | MOption exercise Stock Option (Right to Buy)derivative | -300,000 | $0.00 | $0 | 200,000 | Nov 24, 2025 |
| Nov 19, 2025 | David C. Hanley CHIEF TECHNICAL OPERATIONS | MOption exercise Class A Common Stock | +200,000 | $1.87 | $374k | 224,000 | Nov 21, 2025 |
| Nov 19, 2025 | David C. Hanley CHIEF TECHNICAL OPERATIONS | SOpen-market sale Class A Common Stock | -200,000 | $7.14 | $1.4M | 24,000 | Nov 21, 2025 |
| Nov 19, 2025 | David C. Hanley CHIEF TECHNICAL OPERATIONS | MOption exercise Stock Option (Right to Buy)derivative | -200,000 | $0.00 | $0 | 300,000 | Nov 21, 2025 |
| Nov 17, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Class A Common Stock | +15,000 | $1.87 | $28k | 30,000 | Nov 19, 2025 |
| Nov 17, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | SOpen-market sale Class A Common Stock | -15,000 | $4.77 | $71k | 15,000 | Nov 19, 2025 |
| Nov 19, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Class A Common Stock | +15,000 | $1.87 | $28k | 30,000 | Nov 19, 2025 |
| Nov 19, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | SOpen-market sale Class A Common Stock | -15,000 | $5.10 | $77k | 18,000 | Nov 19, 2025 |
| Nov 17, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Stock Option (Right to Buy)derivative | -15,000 | $0.00 | $0 | 485,000 | Nov 19, 2025 |
| Nov 19, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Stock Option (Right to Buy)derivative | -15,000 | $0.00 | $0 | 470,000 | Nov 19, 2025 |
| Oct 27, 2025 | Gary Hattersley CHIEF SCIENTIFIC OFFICER | MOption exercise Class A Common Stock10b5-1 | +100,000 | $1.74 | $174k | 100,000 | Oct 29, 2025 |
| Oct 27, 2025 | Gary Hattersley CHIEF SCIENTIFIC OFFICER | SOpen-market sale Class A Common Stock10b5-1 | -100,000 | $5.02 | $502k | 0 | Oct 29, 2025 |
| Oct 27, 2025 | Gary Hattersley CHIEF SCIENTIFIC OFFICER | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 298,935 | Oct 29, 2025 |
| Aug 11, 2025 | Robert Mashal director | GGift Stock Option (Right to Buy)derivative | -350,001 | $0.00 | $0 | 391,178 | Aug 13, 2025 |
| Aug 11, 2025 | Robert Mashal director | GGift Stock Option (Right to buy)derivativeindirect: By Trust | +350,001 | $0.00 | $0 | 350,001 | Aug 13, 2025 |
| Jun 18, 2025 | Stacy Markel CHIEF PEOPLE OFFICER | POpen-market purchase Class A Common Stock | +10,000 | $1.71 | $17k | 29,591 | Jun 18, 2025 |
| Jun 16, 2025 | David Hung PRESIDENT AND CEO | POpen-market purchase Class A Common Stock | +500,000 | $1.79 | $894k | 59,281,054 | Jun 18, 2025 |
| Jun 16, 2025 | Kerry Wentworth CHIEF REGULATORY OFFICER | POpen-market purchase Class A Common Stock | +26,000 | $1.79 | $47k | 26,000 | Jun 18, 2025 |
| Jun 16, 2025 | Philippe Sauvage Chief Financial Officer | POpen-market purchase Class A Common Stock | +3,300 | $1.84 | $6,056 | 5,902 | Jun 18, 2025 |
| Jun 16, 2025 | Colleen Sjogren Chief Commercial Officer | POpen-market purchase Class A Common Stock | +50,000 | $1.81 | $90k | 81,000 | Jun 18, 2025 |
| Jun 17, 2025 | Philippe Sauvage Chief Financial Officer | POpen-market purchase Class A Common Stock | +4,000 | $1.79 | $7,160 | 9,902 | Jun 18, 2025 |
| Jun 16, 2025 | Kerry Wentworth CHIEF REGULATORY OFFICER | POpen-market purchase Class A Common Stock | +24,000 | $1.80 | $43k | 50,000 | Jun 18, 2025 |
| May 21, 2025 | W Anthony Vernon director | AGrant or award Stock Option (Right to Buy)derivative | +292,983 | $0.00 | $0 | 292,983 | May 23, 2025 |
| May 21, 2025 | Robert B Bazemore director | AGrant or award Stock Option (Right to Buy)derivative | +292,983 | $0.00 | $0 | 292,983 | May 23, 2025 |
| May 21, 2025 | Robert Mashal director | AGrant or award Stock Option (Right to Buy)derivative | +292,983 | $0.00 | $0 | 292,983 | May 23, 2025 |
| May 21, 2025 | Kathryn E Falberg director | AGrant or award Stock Option (Right to Buy)derivative | +292,983 | $0.00 | $0 | 292,983 | May 23, 2025 |
| May 21, 2025 | Kim D Blickenstaff director | AGrant or award Stock Option (Right to Buy)derivative | +292,983 | $0.00 | $0 | 292,983 | May 23, 2025 |
| May 2, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Class A Common Stock10b5-1 | +20,000 | $1.94 | $39k | 32,000 | May 6, 2025 |
| May 2, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $2.50 | $50k | 12,000 | May 6, 2025 |
| May 2, 2025 | Dongfang Liu CHIEF MEDICAL OFFICER | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -20,000 | $1.94 | $39k | 480,000 | May 6, 2025 |
| Apr 4, 2025 | David Hung PRESIDENT AND CEO | POpen-market purchase Class A Common Stock | +200,000 | $1.66 | $333k | 58,481,054 | Apr 8, 2025 |
| Apr 7, 2025 | David Hung PRESIDENT AND CEO | POpen-market purchase Class A Common Stock | +300,000 | $1.63 | $488k | 58,781,054 | Apr 8, 2025 |
| Apr 1, 2025 | Robert Mashal director | POpen-market purchase Class A Common Stockindirect: By Trust | +1,100 | $1.67 | $1,832 | 101,100 | Apr 3, 2025 |
| Apr 1, 2025 | Robert Mashal director | POpen-market purchase Class A Common Stockindirect: By Trust | +98,900 | $1.67 | $165k | 200,000 | Apr 3, 2025 |
| Feb 28, 2025 | Gary Hattersley CHIEF SCIENTIFIC OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Mar 4, 2025 |
| Feb 28, 2025 | David Hung PRESIDENT AND CEO | AGrant or award Stock Option (Right to Buy)derivative | +2,000,000 | $0.00 | $0 | 2,000,000 | Mar 4, 2025 |
| Feb 28, 2025 | David C. Hanley CHIEF TECHNICAL OPERATIONS | AGrant or award Stock Option (Right to Buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Mar 4, 2025 |
| Nov 11, 2024 | Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD. | SOpen-market sale Class A Common Stock | -56,361 | $2.89 | $163k | 3,866,228 | Nov 13, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Kim D Blickenstaffdirector
- Robert B Bazemoredirector
- Xiangmin Cuiowner, director
- Kathryn E Falbergdirector
- David C. HanleyCHIEF TECHNICAL OPERATIONS
- Gary HattersleyCHIEF SCIENTIFIC OFFICER
- David HungPRESIDENT AND CEO
- Dongfang LiuCHIEF MEDICAL OFFICER
- Moses MakunjeSEE REMARKS
- Stacy MarkelCHIEF PEOPLE OFFICER
- Robert Mashaldirector
- Philippe SauvageChief Financial Officer
- Colleen SjogrenChief Commercial Officer
- W Anthony Vernondirector
- Junyuan Jerry WangCEO, ANHEART THERAPEUTICS LTD.
- Kerry WentworthCHIEF REGULATORY OFFICER
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.